New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline.SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public.SO WHAT: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations during the class period [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of critical information regarding stock price manipulation [5].

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of monday.com Ltd. (NASDAQ: MNDY) between September 17, 2025 and February 6, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. SO WHAT: If you purchased monday.com common stock during the Class Perio ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Trip.com Group Limited securities between April 30, 2024, and January 13, 2026, of the May 11, 2026, deadline to become lead plaintiffs in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Trip.com securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by May 11, 2026, to serve as lead plaintiffs, representing other class members in the litigation [3]. - The lawsuit alleges that defendants made false or misleading statements and failed to disclose regulatory risks associated with Trip.com's monopolistic business practices, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 alone [4].

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lufax Holding Ltd (NYSE: LU) resulting from allegations that Lufax may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Lufax securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from June 5, 2023, to December 26, 2025 [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with misleading information regarding the expected results of their Phase 3 studies for setrusumab in Osteogenesis Imperfecta (OI), which ultimately did not meet their primary endpoints [5][6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information was revealed [6].

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”), of the important April 20, 2026 lead plaintiff deadline. SO WHAT: If you purchased Enphase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D ...

Group 1 - A class action lawsuit has been filed on behalf of purchasers of common stock of Alight, Inc. (NYSE: ALIT) for the period between November 12, 2024, and February 18, 2026 [1] - Investors who purchased Alight common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Alight made false and misleading statements regarding its growth potential and financial stability, failing to disclose that it could not maintain its promised dividend [5] Group 2 - The Rosen Law Firm, which is representing the investors, has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4] - Investors interested in joining the class action can find more information through the Rosen Law Firm's website or by contacting them directly [3][6]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. for the period between March 26, 2025, and November 4, 2025, due to alleged misleading statements regarding the safety and commercial viability of its product DCCR [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Soleno Therapeutics made false and misleading statements about the safety of DCCR, particularly concerning significant safety concerns related to excess fluid retention in clinical trial participants [5]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and securing over $438 million for investors in 2019 [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].